Before the Open (Oct 13)

Good morning. Happy Friday.
The Asian/Pacific markets closed mostly up. Japan, China, Hong Kong, India, Singapore and the Philippines did the best. Europe, Africa and the Middle East lean to the upside. Greece and Austria are up more than 1%; the UAE, Russia, the Netherlands, Italy and Saudi Arabia are also doing well. Denmark is down. Futures in the States point towards an up open for the cash market.
—————
VIDEO: There’s a Bull Market Somewhere
—————
The dollar is up. Oil and copper are up. Gold and silver are down. Bonds are down.
Stock headlines from barchart.com…
General Motors (GM -1.28%) was upgraded to ‘Overweight’ from ‘Equal-weight’ at Barclays with a price target of $55.
Saratoga Investment (SAR +1.46%) was upgraded to ‘Buy’ from ‘Neutral’ at Compass Point Research & Trading LLS with a price target of $23.
Dollar Tree (DLTR +0.15%) was downgraded to ‘Hold’ from ‘Buy’ at Loop Capital Markets.
Ford Motor (F -2.10%) was downgraded to ‘Equal-weight’ from ‘Overweight’ at Barclays.
Hostess Brands (TWNK -0.37%) was downgraded to ‘Sell’ from ‘Neutral’ at UBS with a price target of $11.
Nanometrics (NANO +0.03%) dropped nearly 6% in after-hours trading after it reported preliminary Q3 EPS of 20 cents-22 cents weaker than consensus of 27 cents.
Spark Therapeutics (ONCE -0.62%) rallied over 5% in after-hours trading after an FDA advisory committee voted 16-0 in favor of Spark’s Luxturna for treatment in patients with vision loss due to balletic mutation-associated retinal dystrophy.
Applied Optoelectronic (AAOI -4.23%) tumbled over 15% in after-hours trading after it announced preliminary Q3 revenue of $88 million-$89 million, below prior guidance of $107 million-$115 million.
Endocyte (ECYT +0.41%) dropped 9% in after-hours trading after it filed to sell $150 million in a mixed-securities shelf offering.
EXFO Inc (EXFO +0.75%) jumped 12% in after-hours trading after it reported Q4 revenue of $63 million, above consensus of $60.9 million.
Antares Pharma (ATRS -5.33%) plunged 30% in after-hours trading after the FDA said as part of their ongoing review of the company’s New Drug Application for its Xyosted injection that it has identified deficiencies that preclude the continuation of labeling and postmarking requirements at this time.
Tandem Diabetes Care (TNDM -17.89%) slumped over 25% in after-hours trading after it offered 3.2 million shares of common stock at $3.50 each, a 25% discount to Thursday’s close.
—————
Join our email list – get technical research reports sent directly to you.
—————
Thursday’s Key Earnings
EXFO (NASDAQ:EXFO) +13.6% AH on Q4 earnings and better than expected Q1 guidance.
Today’s Economic Calendar
8:30 Consumer Price Index
8:30 Retail Sales
8:30 Fed’s Rosengren speech
9:00 Janet Yellen Speech on Sunday
10:00 Business Inventories
10:00 Consumer Sentiment
11:30 Fed’s Kaplan speech
1:00 PM Baker-Hughes Rig Count
1:00 PM Fed’s Powell speech
2:00 PM Treasury Budget
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY